ACE2 is the receptor for SARS-CoV-2 [29–31], which is responsible for the COVID-19 outbreak, giving rise to the following two questions: will renal injury be increased in COVID-19 patients with diabetes and will ACEi/ARB treatment have an impact on the renal outcome of COVID-19 patients with diabetes? Here, ACE2 is linked to COVID-19.